Detecting Medication Risks among People in Need of Care: Performance of Six Instruments.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
28 01 2023
Historique:
received: 22 12 2022
revised: 23 01 2023
accepted: 26 01 2023
entrez: 11 2 2023
pubmed: 12 2 2023
medline: 15 2 2023
Statut: epublish

Résumé

Numerous tools exist to detect potentially inappropriate medication (PIM) and potential prescribing omissions (PPO) in older people, but it remains unclear which tools may be most relevant in which setting. This cross sectional study compares six validated tools in terms of PIM and PPO detection. We examined the PIM/PPO prevalence for all tools combined and the sensitivity of each tool. The pairwise agreement between tools was determined using Cohen's Kappa. We included 226 patients in need of care (median (IQR age 84 (80-89)). The overall PIM prevalence was 91.6 (95% CI, 87.2-94.9)% and the overall PPO prevalence was 63.7 (57.1-69.9%)%. The detected PIM prevalence ranged from 76.5%, for FORTA-C/D, to 6.6% for anticholinergic drugs (German-ACB). The PPO prevalences for START (63.7%) and FORTA-A (62.8%) were similar. The pairwise agreement between tools was poor to moderate. The sensitivity of PIM detection was highest for FORTA-C/D (55.1%), and increased to 79.2% when distinct items from STOPP were added. Using a single screening tool may not have sufficient sensitivity to detect PIMs and PPOs. Further research is required to optimize the composition of PIM and PPO tools in different settings.

Identifiants

pubmed: 36767705
pii: ijerph20032327
doi: 10.3390/ijerph20032327
pmc: PMC9915255
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Lancet. 2012 Jul 7;380(9836):37-43
pubmed: 22579043
Age Ageing. 2022 Jan 6;51(1):
pubmed: 34673915
CMAJ. 2005 Aug 30;173(5):489-95
pubmed: 16129869
Dtsch Arztebl Int. 2010 Aug;107(31-32):543-51
pubmed: 20827352
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
PLoS One. 2016 Feb 03;11(2):e0146811
pubmed: 26840396
Eur J Clin Pharmacol. 2015 Dec;71(12):1415-27
pubmed: 26407687
Eur J Clin Pharmacol. 2021 Feb;77(2):147-162
pubmed: 33011824
Int J Med Inform. 2019 May;125:110-117
pubmed: 30914175
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Br J Clin Pharmacol. 2004 Jan;57(1):6-14
pubmed: 14678335
Med Care. 2002 Sep;40(9):771-81
pubmed: 12218768
Drugs Aging. 2022 Mar;39(3):245-247
pubmed: 35194722
Neurology. 2010 Jul 13;75(2):152-9
pubmed: 20625168
Eur J Clin Pharmacol. 2014 Jan;70(1):1-11
pubmed: 24019054
BMC Geriatr. 2020 Jun 1;20(1):190
pubmed: 32487225
Age Ageing. 2021 Jun 28;50(4):1189-1199
pubmed: 33349863
BMC Geriatr. 2018 Oct 11;18(1):239
pubmed: 30305048
Age Ageing. 2015 Mar;44(2):213-8
pubmed: 25324330
Ann Pharmacother. 2011 Jul;45(7-8):977-89
pubmed: 21693697
PLoS One. 2019 Jun 13;14(6):e0218174
pubmed: 31194800
Ther Adv Drug Saf. 2022 Jul 4;13:20420986221100117
pubmed: 35814333
BMJ Open. 2021 Sep 17;11(9):e050344
pubmed: 34535481
Eur J Clin Pharmacol. 2015 Jul;71(7):861-75
pubmed: 25967540
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Health Syst Transit. 2020 Dec;22(6):1-272
pubmed: 34232120
Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:661-681
pubmed: 31589822

Auteurs

Tobias Dreischulte (T)

Institute of General Practice and Family Medicine, University Hospital, LMU Munich, 80336 Munich, Germany.

Linda Sanftenberg (L)

Institute of General Practice and Family Medicine, University Hospital, LMU Munich, 80336 Munich, Germany.

Philipp Hennigs (P)

Institute of General Practice and Family Medicine, University Hospital, LMU Munich, 80336 Munich, Germany.

Isabel Zöllinger (I)

Institute of General Practice and Family Medicine, University Hospital, LMU Munich, 80336 Munich, Germany.

Rita Schwaiger (R)

Institute of General Practice and Family Medicine, University Hospital, LMU Munich, 80336 Munich, Germany.

Caroline Floto (C)

Institute of General Practice, Friedrich-Alexander-University of Erlangen-Nuremberg, 91054 Erlangen, Germany.

Maria Sebastiao (M)

Institute of General Practice, Friedrich-Alexander-University of Erlangen-Nuremberg, 91054 Erlangen, Germany.

Thomas Kühlein (T)

Institute of General Practice, Friedrich-Alexander-University of Erlangen-Nuremberg, 91054 Erlangen, Germany.

Dagmar Hindenburg (D)

Institute of General Practice, University Hospital of Julius-Maximilians-Universität Würzburg, 97070 Würzburg, Germany.

Ildikó Gagyor (I)

Institute of General Practice, University Hospital of Julius-Maximilians-Universität Würzburg, 97070 Würzburg, Germany.

Domenika Wildgruber (D)

Katholische Stiftungshochschule München/University of Applied Sciences, 81667 Munich, Germany.

Anita Hausen (A)

Katholische Stiftungshochschule München/University of Applied Sciences, 81667 Munich, Germany.

Christian Janke (C)

Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of LMU Munich, 80802 Munich, Germany.

Michael Hölscher (M)

Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of LMU Munich, 80802 Munich, Germany.

Daniel Teupser (D)

Institute of Laboratory Medicine, University Hospital of LMU Munich, 81377 Munich, Germany.

Jochen Gensichen (J)

Institute of General Practice and Family Medicine, University Hospital, LMU Munich, 80336 Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH